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Since epidemiological cutoff values (ECVs) using CLSI MICs frommultiple laboratories are not available for Candida spp. and
the echinocandins, we established ECVs for anidulafungin andmicafungin on the basis of wild-type (WT)MIC distributions (for
organisms in a species-drug combination with no detectable acquired resistance mechanisms) for 8,210 Candida albicans, 3,102
C. glabrata, 3,976 C. parapsilosis, 2,042 C. tropicalis, 617 C. krusei, 258 C. lusitaniae, 234 C. guilliermondii, and 131 C. dublini-
ensis isolates. CLSI broth microdilutionMIC data gathered from 15 different laboratories in Canada, Europe, Mexico, Peru, and
the United States were aggregated to statistically define ECVs. ECVs encompassing 97.5% of the statistically modeled population
for anidulafungin and micafungin were, respectively, 0.12 and 0.03g/ml for C. albicans, 0.12 and 0.03g/ml for C. glabrata, 8
and 4g/ml for C. parapsilosis, 0.12 and 0.06g/ml for C. tropicalis, 0.25 and 0.25g/ml for C. krusei, 1 and 0.5g/ml for C.
lusitaniae, 8 and 2g/ml for C. guilliermondii, and 0.12 and 0.12g/ml for C. dubliniensis. Previously reported single and mul-
ticenter ECVs defined in the present study were quite similar or within 1 2-fold dilution of each other. For a collection of 230WT
isolates (no fksmutations) and 51 isolates with fksmutations, the species-specific ECVs for anidulafungin andmicafungin cor-
rectly classified 47 (92.2%) and 51 (100%) of the fksmutants, respectively, as non-WT strains. These ECVsmay aid in detecting
non-WT isolates with reduced susceptibility to anidulafungin andmicafungin due to fksmutations.
The echinocandins anidulafungin and micafungin are widelyrecognized as first-line antifungal agents for the treatment of
candidemia and other forms of invasive candidiasis (infections of
normally sterile sites, tissues, and organs) (1–3). The Clinical and
Laboratory Standards Institute (CLSI) Subcommittee onAntifun-
gal Susceptibility Tests has standardized the broth microdilution
reference method for testing the echinocandins against Candida
spp. (4) and has developed new species-specific clinical break-
points (CBPs) for the more prevalent species (Candida albicans, C.
glabrata, C. guilliermondii, C. krusei, C. parapsilosis, and C. tropi-
calis) (5–7); epidemiological cutoff values (ECVs) for common
and less prevalent species (e.g., C. dubliniensis, C. guilliermondii,
andC. lusitaniae) have also been defined (6–8).Whereas CBPs are
used to identify those isolates that are likely to respond to treat-
ment with a given antimicrobial agent administered at the ap-
proved closing regimen for that agent, the ECV can be used as the
most sensitive indicator of the emergence of strains with reduced
susceptibility to a given agent (6, 9–12). An ECV is anMIC thresh-
old value that allows the discrimination of wild-type (WT) strains
(those without mutational or acquired resistance mechanisms)
from non-WT strains (those harboring mutational or acquired
resistance mechanisms) (6, 7, 9, 10, 12).
The species-specific ECVs defined previously for all three echi-
nocandins (anidulafungin, caspofungin, and micafungin) were
determined using CLSI MIC results from a single laboratory (8,
13). Because MIC distributions generated by a single laboratory
may not be completely representative of WT MICs for all agents
and species of Candida (14), we further validated these ECVs for
anidulafungin and micafungin by gathering MIC data from mul-
tiple laboratories (15 different centers) in Canada, Europe, Mex-
ico, Peru, and the United States. MIC data were also collected for
caspofungin; however, due to excessive heterogeneity in the re-
spective MIC distributions, the caspofungin results are presented
separately (14). Although the number of isolates needed to calcu-
late a representative ECV is not established, there is a working
consensus among experts that recommends at least 50 strains
(and, preferably, 100) from at least 3 to 5 different laboratories
(15, 16).
Themain objectives of the present study included (i) definition
of theWTMICdistributions of anidulafungin andmicafungin for
five of the most common and three less common Candida species
causing invasive candidiasis by using aggregated CLSIMIC results
from 15 different laboratories (131 to 8,210 MICs, according to
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species and antifungal agent), (ii) proposal of the ECV for each
species-drug combination for the 24-h CLSI method, (iii) com-
parison of the ECVs obtained from this multicenter study with
those previously proposed by a single laboratory and those re-
cently determined in a multicenter study for the Sensititre Yeast-
One method (17), and (iv) demonstration of the ability of these
ECVs to discriminateWT from non-WT strains of Candida using
a collection of 230 WT isolates (no fks mutations) and 51 isolates
with fks mutations.
MATERIALS AND METHODS
Isolates. Each isolate was recovered from a unique clinical specimen at 15
different centers or reference laboratories: The University of Iowa, Iowa
City, IA; JMI Laboratories, North Liberty, IA; VCUMedical Center, Rich-
mond, VA; Instituto de Medicina Tropical Alexander von Humboldt-
Universidad Peruana Cayetano Heredia, Lima, Peru; Hospital Universi-
tario La Fe, Valencia, Spain; University of Texas Health Science Center,
San Antonio, TX; University of Alberta, Edmonton, Alberta, Canada;
Universidad Autónoma de Nuevo León,Monterey, Nuevo León,Mexico;
Facultat de Medicina, IISPV, URV, Reus, Spain; The Innsbruck Medical
University, Innsbruck, Austria; Centers for Disease Control and Preven-
tion, Atlanta, GA; Hospital Universitario de Valme, Seville, Spain; Cani-
sius Wilhelmina Hospital and Radboud University, Nijmegen Medical
Center, Nijmegen, Netherlands; University of Texas Health Science Cen-
ter, Houston, TX; Hospital General Universitario Gregorio Maranˇón,
Facultad de Medicina-Universidad Complutense, Madrid, Spain; and
Laboratoire de Santé Publique duQuébec, InstitutNational de Santé Pub-
lique du Québec, Quebec, Quebec, Canada. These laboratories were
coded 1 to 20 (for several studies), but because some laboratories were
excluded from the study or did not provide echinocandin data, we used
data from the remaining 15 laboratories (Table 1). Isolates were identified
and stored at eachmedical center using standardized nonmolecularmeth-
odologies; isolates were not characterized for mutations. The total num-
bers of aggregated available CLSI MICs from the 15 laboratories per spe-
cies were as follows: 8,210 forC. albicans, 3,102 forC. glabrata, 3,976 forC.
parapsilosis, 2,042 for C. tropicalis, 617 for C. krusei, 258 for C. lusitaniae,
234 for C. guilliermondii, and 131 for C. dubliniensis.
Whereas these isolates generally represented the incident isolate for
each episode of infection and were likely WT strains, the extent of prior
exposure to antifungal therapy is not known. This must be recognized as
a possible limitation of the study, as prior exposuremay result in acquired
antifungal resistance, skewing the results.
In addition to these isolates, we included the anidulafungin andmica-
fungin MIC distributions from an earlier collection of 281 isolates (5
species; 230 WT and 51 non-WT) all tested for the presence (non-WT)
and absence (WT) of mutations in fks1 and fks2 (C. glabrata only) (6, 10)
in order to assess the ability of the various anidulafungin and micafungin
ECVs to discriminate non-WT fromWT strains of Candida at the molec-
ular level.
Antifungal susceptibility testing. Broth microdilution testing was
performed in each laboratory in accordance with the guidelines in CLSI
document M27-A3 (4), using RPMI 1640 medium with 0.2% glucose, an
inoculum of 0.5 103 to 2.5 103 cells/ml, and incubation in air at 35°C.
MIC values were determined visually after 24 h of incubation as the lowest
concentration of drug that caused a significant diminution (50% inhi-
bition) of growth relative to that of the growth control (4). In all instances,
MIC trays were prepared using reagent-grade powders, as directed by
CLSI.
Two quality control (QC) isolates, C. parapsilosis ATCC 22019 and C.
krusei ATCC 6258, were used on each day of testing by the participant
laboratories, as recommended by CLSI (4, 5). Only those results for which
QC MICs were within the established reference range were used in the
study.
Definitions. The definitions of the WT population and ECV were
those reported previously (6, 8, 9, 16). AWT population was the subpop-
ulation of isolates/MICs for a species-drug combination with no acquired
detectable resistance mechanisms (12, 17).
The ECV is the highest MIC value of the WT population. It is calcu-
lated by taking into account theMIC distribution, themodalMIC of each
distribution, and the inherent variability of the test (usually within 1 dou-
bling dilution) and should encompass95% of isolates (7).
Data analysis. The MIC distributions of each of the eight species
tested in each participant laboratory were first screened for evidence of
grossly skewed distributions that precluded statistical fitting, and the
modalMICs for each laboratory were determined (14, 16); however, their
pseudomodes were the same as those observed in the laboratories in-
cluded in the analysis. Grossly skewed distributions and distributions
which had amodalMIC at the lowest concentration tested were excluded.
Next, the aggregateWTdistributions for each antifungal agent and species
of Candida were obtained by pooling qualifying MIC distributions from
participant laboratories, and the ECVwas then estimated by the statistical
method of Turnidge et al. (18). For this study, a minimum of 3 laborato-
ries and 100 data points was required to establish a reasonable estimated
ECV for a given agent and species. In the statistical method, the modeled
WT population is based on fitting a lognormal distribution at the lower
end of theMIC range, calculating themean and standard deviation of that
normal distribution, and using those values to estimate the MIC (ECV)
that captured at least 95%, 97.5%, and 99% of the modeled WT popula-
tion, rounded up to the nearest 2-fold dilution. The modes for each agent
and species and the inherent variability (within approximately 1 doubling
dilution) of susceptibility testing were also considered, and a search for
outlier laboratories in each distribution was performed (19).
RESULTS AND DISCUSSION
A total of 17 laboratories submitted MIC data for anidulafungin
and micafungin; data for 2 laboratories were omitted due to the
use of 2.0% glucose (rather than the 0.2% glucose prescribed by
CLSI) in the test medium (4). In addition, MICs for some species
and antifungal agent combinations from 1 and 5 laboratories, re-
spectively, were not included in the final analysis due to truncated
distributions (modalMIC at the lowest concentration tested). The
remaining aggregated CLSI MIC distributions from the 15 labo-
ratories for the various species versus anidulafungin andmicafun-
gin were 8,210 and 7,874, respectively, for C. albicans, 2,680 and
3,102, respectively, for C. glabrata, 3,976 and 3,484, respectively,
for C. parapsilosis, 2,042 and 1,605, respectively, for C. tropicalis,
322 and 617, respectively, for C. krusei, 234 and 258, respectively,
for C. lusitaniae, 222 and 234, respectively, for C. guilliermondii,
and 131 and 117, respectively, for C. dubliniensis (Tables 1 to 3).
The data in Table 1 include the number of MIC results and the
range andmodal MIC values for each laboratory that contributed
qualifying data for the different drug-organism combinations.
These results demonstrate the comparability of the MIC distribu-
tions contributed by the various laboratories for each antifungal
agent and species of Candida. With few exceptions, the modal
MICs for each laboratory were within 1 2-fold dilution of one
another within the different drug-organism pairs.
The pooled WT MIC distributions for anidulafungin and mi-
cafungin and each of the eight species of Candida are shown in
Table 2. The in vitro activities of the 2 antifungal agents testedwere
similar to those observed by other authors using the CLSI method
(20–22). All of the MIC distributions were typical for WT organ-
isms and covered 3 to 5 2-fold dilution steps surrounding the
modal MIC.
Table 3 depicts the proposed anidulafungin and micafungin
ECVs (using 95%, 97.5%, and 99% of the modeled MIC
population) as well as themodalMICs for each of the eight species
ECVs for Candida and Echinocandins
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TABLE 1 MIC distributions of anidulafungin and micafungin for eight species of Candida and each contributing laboratory determined using CLSI
M27-A3 broth microdilution methods
Antifungal agent
Species (total no. of
isolates tested) Laboratory
No. of isolates
tested
MIC (g/ml)
Range Mode
Anidulafungin C. albicans (8,210) 1 336 0.008–0.5 0.03
2 138 0.015–0.25 0.03
3 363 0.008–2 0.015
9 447 0.008–2 0.03
12 1,246 0.008–1 0.03
18 1,397 0.008–2 0.015
19 4,283 0.008–1 0.03
C. glabrata (2,680) 1 106 0.015–2 0.06
2 121 0.015–2 0.03
3 98 0.015–4 0.03
6 40 0.015–0.12 0.06
18 1,079 0.008–4 0.03
19 1,236 0.015–4 0.06
C. parapsilosis (3,976) 1 28 0.12–4 1
2 81 0.12–4 0.5
3 246 0.015–4 2
9 159 0.015–4 2
10 391 0.03–4 1
11 275 0.03–8 2
12 878 0.03–4 1
14 44 0.03–2 1
17 31 0.12–2 1
18 599 0.008–8 1
19 1,238 0.015–4 2
20 6 0.03–2 1
C. tropicalis (2,042) 1 36 0.015–1 0.06
2 49 0.015–0.25 0.03
3 55 0.015–2 0.03
6 45 0.015–0.25 0.03
9 72 0.015–0.25 0.03
12 425 0.008–2 0.06
18 364 0.008–0.5 0.015
19 996 0.008–2 0.03
C. krusei (322) 1 20 0.03–1 0.06
2 29 0.03–0.25 0.12
3 19 0.03–2 0.03
6 2 0.06–2 0.06
9 25 0.06–0.25 0.12
11 79 0.03–2 0.06
12 83 0.03–2 0.06
18 54 0.015–0.25 0.03
20 11 0.015–0.12 0.03
C. lusitaniae (234) 1 20 0.06–0.5 0.25
2 12 0.06–1 0.25
9 35 0.06–1 0.25
12 9 0.06–1 0.25
18 59 0.008–1 0.5
19 99 0.06–1 0.5
C. guilliermondii (222) 1 9 0.25–4 2
6 2 1 1
9 6 0.5–2 2
11 8 1–2 1
12 91 0.03–4 1
14 3 0.06–1 1
18 15 0.25–4 1
19 88 0.06–4 1
C. dubliniensis (131) 1 38 0.015–4 0.06
5 11 0.015–0.25 0.06
9 14 0.015–0.12 0.03
(Continued on following page)
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TABLE 1 (Continued)
Antifungal agent
Species (total no. of
isolates tested) Laboratory
No. of isolates
tested
MIC (g/ml)
Range Mode
11 5 0.015–0.03 0.03
18 63 0.015–1 0.06
Micafungin C. albicans (7,874) 1 95 0.008–0.5 0.015
3 366 0.008–2 0.015
9 447 0.015–4 0.03
12 1,246 0.008–1 0.03
18 1,398 0.008–2 0.015
19 4,282 0.008–0.5 0.015
20 40 0.008–1 0.015
C. glabrata (3,102) 1 52 0.008–0.12 0.03
2 284 0.015–4 0.03
3 97 0.008–1 0.015
9 164 0.015–0.12 0.03
12 176 0.008–2 0.015
18 1,079 0.008–32 0.015
19 1,236 0.008–2 0.015
20 14 0.015–4 0.015
C. parapsilosis (3,484) 1 32 0.06–4 1
2 239 0.06–2 0.5
3 251 0.015–4 1
4 27 0.015–1 0.5
9 159 0.25–4 1
11 55 0.03–2 1
12 878 0.015–4 1
18 599 0.015–4 1
19 1,238 0.015–2 1
20 6 0.015–2 1
C. tropicalis (1,605) 1 39 0.008–0.12 0.015
3 53 0.008–4 0.015
8 45 0.015–8 0.03
9 72 0.008–0.25 0.06
11 32 0.008–0.06 0.03
18 363 0.008–1 0.03
19 996 0.008–1 0.015
20 5 0.008–0.06 0.03
C. krusei (617) 1 41 0.03–1 0.12
2 72 0.015–0.25 0.12
3 21 0.015–1 0.12
4 60 0.03–0.5 0.12
11 5 0.03–0.06 0.06
12 83 0.015–0.25 0.12
18 54 0.06–0.12 0.12
19 270 0.015–0.25 0.06
20 11 0.03–0.12 0.06
C. lusitaniae (258) 2 56 0.015–16 0.12
9 35 0.03–0.5 0.25
12 9 0.015–0.5 0.12
18 59 0.015–2 0.25
19 99 0.008–1 0.12
C. guilliermondii (234) 1 13 0.03–0.5 0.25
2 27 0.06–0.25 0.25
11 91 0.015–8 0.5
18 14 0.25–2 0.25
19 88 0.015–8 0.5
20 1 0.25 0.25
C. dubliniensis (117) 2 27 0.015–2 0.03
3 1 0.015 0.015
9 10 0.03–0.06 0.03
17 63 0.008–1 0.06
18 16 0.015–8 0.06
ECVs for Candida and Echinocandins
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ofCandida. Very little difference between the ECVs encompassing
95%, 97.5%, or 99% of the modeled MIC populations was seen.
While previous studies have reported ECVs to be theMIC encom-
passing at least 95% of the population defined using both the
eyeball method and statistical methods for Candida spp. (7, 13)
and Aspergillus spp. (16), for comparison purposes we used the
ECV that encompassed 97.5% of the modeled population; these
ECVs appeared to relate better to those defined by the eyeball
method (18). In general, the ECVs for each antifungal agent and
species ofCandidawerewithin 1 or 2 2-fold dilutions of themodal
MICvalues. Likewise, the ECVs for anidulafungin andmicafungin
and each species of Candida were within 1 to 2 2-fold dilutions of
one another, with those of anidulafungin usually being higher
than those of micafungin.
The ECVs defined in the present study are similar to those
reported previously from a single laboratory using the CLSI broth
microdilution method as well as those reported by Canton et al.
(17) using the Sensititre YeastOne method. In each case, the
method for calculating the ECVs was that of Turnidge et al. (18);
however, the single-laboratory CLSI study and the multicenter
YeastOne study used the 95% threshold, while in the present
study, ECVs encompassing 97.5% of the modeled population
were also defined (Table 3). In general, 100% of the ECVs from
both the single-laboratory CLSI study and the YeastOne study
TABLE 2 Pooled MIC distributions of anidulafungin and micafungin for eight species of Candida from 5 to 12 laboratories using CLSI M27-A3
method
Antifungal
agent
Species (no. of isolates
tested)
No. of isolates with MIC (g/ml) ofa:
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16
Anidulafungin C. albicans (8,210) 752 2,582 2,823 1,410 413 132 71 21 6
C. glabrata (2,680) 2 66 728 1,316 456 40 23 16 22 11
C. parapsilosis (3,976) 1 15 66 77 109 196 541 1,202 1,523 244 2
C. tropicalis (2,042) 152 449 784 419 140 47 32 11 8
C. krusei (322) 7 14 95 119 46 20 7 10 4
C. lusitaniae (234) 1 1 15 32 95 77 13
C. guilliermondii (222) 1 8 12 19 31 84 54 13
C. dubliniensis (131) 21 47 47 9 3 1 1 1 1
Micafungin C. albicans (7,874) 746 4,223 1,999 465 184 146 82 21 6 2
C. glabrata (3,102) 318 1,931 596 124 40 26 20 16 18 12
C. parapsilosis (3,484) 23 8 15 50 289 811 1,581 674 33
C. tropicalis (1,605) 71 598 588 270 54 14 2 6 1 1
C. krusei (617) 18 52 297 198 47 3 2
C. lusitaniae (258) 1 7 14 24 91 101 13 1 4 2
C. guilliermondii (234) 5 8 19 25 60 67 38 7 3 2
C. dubliniensis (117) 1 5 43 55 5 1 1 1 5
a Shaded values indicate the modes (the most frequent MIC).
TABLE 3 Anidulafungin and micafungin ECVs for eight species of Candida based on MICs from 5 to 12 laboratories determined by the CLSI M27-
A3 broth microdilution method
Antifungal
agent tested Species
No. of
isolates
MIC (g/ml) ECV (g/ml)a
Range Modeb 95% 97.5% 99%
Anidulafungin C. albicans 8,210 0.008–2 0.03 0.06 0.12 0.12
C. glabrata 2,680 0.008–4 0.06 0.12 0.12 0.25
C. parapsilosis 3,976 0.008–8 2 4 8 8
C. tropicalis 2,042 0.008–2 0.03 0.12 0.12 0.12
C. krusei 322 0.008–2 0.06 0.12 0.25 0.25
C. lusitaniae 234 0.008–1 0.25 1 1 1
C. guilliermondii 222 0.03–4 1 4 8 8
C. dubliniensis 131 0.015–4 0.03 0.12 0.12 0.12
Micafungin C. albicans 7,874 0.008–4 0.015 0.03 0.03 0.03
C. glabrata 3,102 0.008–4 0.015 0.03 0.03 0.03
C. parapsilosis 3,484 0.015–4 1 2 4 4
C. tropicalis 1,605 0.008–8 0.015 0.06 0.06 0.12
C. krusei 617 0.015–1 0.06 0.25 0.25 0.25
C. lusitaniae 258 0.008-16 0.25 0.5 0.5 1
C. guilliermondii 234 0.015–8 0.5 2 2 4
C. dubliniensis 117 0.008–8 0.06 0.12 0.12 0.12
a Calculated ECVs comprising95%,97.5%, or99% of the statistically modeled MIC population.
b The most frequent MIC.
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were equal to or within 1 2-fold dilution of those reported in the
present multicenter study (ECVs comprising 97.5% of the popu-
lation), except for the higher YeastOne ECV of anidulafungin for
C. tropicalis (1g/ml versus 0.12g/ml). Previous comparison of
MICs obtained by the YeastOne and CLSI methods provided
comparable results (23, 24). Regarding the European Committee
on Antimicrobial Susceptibility Testing (EUCAST-AFST) cutoff
values for Candida and the echinocandins, this organization has
established breakpoints for anidulafungin and C. albicans (0.03
g/ml),C. glabrata (0.06g/ml),C. krusei (0.06g/ml), andC.
tropicalis (0.06 g/ml) and, more recently, for micafungin and C.
albicans (0.01g/ml),C. glabrata (0.03g/ml), andC. parap-
silosis (0.002 g/ml) (http://www.EUCAST.org).
The ability of the ECVs encompassing 97.5% of the statistically
modeled population to differentiate strains of Candida with ac-
quired mechanisms of resistance to the echinocandins (e.g., mu-
tations in fks1 or fks2) may be seen in the data presented in Table
4. The isolates in the collection for which the results are depicted
in Table 4 were selected from global and population-based sur-
veillance and reference collections to represent both WT and
non-WT isolates with availableMIC results for anidulafungin and
micafungin, and all isolates were previously characterized regard-
ing the presence or absence of mutations in the hot-spot (HS)
regions of fks1 (C. albicans,C. glabrata,C. tropicalis,C. krusei, and
C. dubliniensis) and fks2 (C. glabrataonly) (6, 10, 25–27). A total of
51 isolates harboredmutations in either fks1 or fks2: 11C. albicans
isolates, 30 C. glabrata isolates, 6 C. tropicalis isolates, 3 C. krusei
isolates, and 1 C. dubliniensis isolate. The ECVs for anidulafungin
and C. albicans, C. glabrata, C. tropicalis, and C. dubliniensis were
all 0.12 g/ml, and the ECV for C. krusei was 0.25 g/ml (Table 3
and Table 4). Using these cutoffs, the CLSI method correctly clas-
sified 47 (92.2%) of the 51 mutant strains as non-WT (for which
the MIC was greater than the ECV) and 223 (97.0%) of 230 WT
strains (with no fks mutation) as WT. The ECVs for micafungin
and C. albicans, C. glabrata, C. tropicalis, C. krusei, and C. dublini-
ensis were 0.03 g/ml, 0.03 g/ml, 0.06 g/ml, 0.25 g/ml, and
0.12 g/ml, respectively (Tables 3 and 4). Using these ECVs, the
CLSI method with micafungin correctly classified all 51 mutant
strains as non-WT and 194 (84.3%) of 230WT strains (for which
theMIC was less than or equal to the ECV) asWT. The reason for
these misclassifications could be due to an alternative mechanism
of resistance (WT as non-WT) or could simply be reflective of the
crossing over of WT and non-WT MIC distributions; unfortu-
nately, there is no enough clinical information about these strains.
In summary, MIC data originating in 5 to 12 laboratories in 7
different countries have enabled us to propose species-specific
ECVs for anidulafungin and micafungin and eight different spe-
cies of Candida. We present ECVs that encompass 95%, 97.5%,
and 99% of the statistically modeled population and recommend
that the ECVs encompassing 97.5% be used to differentiate WT
from non-WT strains of Candida for both echinocandins. The
robust nature of these ECVs is demonstrated by comparison with
those generated in another multicenter study using the YeastOne
method as well as those generated in a single-center study using
the CLSI method. Furthermore, we demonstrate the ability of the
species-specific ECVs for both echinocandins to identify fks mu-
tant strains in a population of 281 well-characterized Candida
species. Although either anidulafungin or micafungin testing
proved very sensitive in detecting the fks mutant strains, testing
withmicafungin tended tomisclassify some isolates ofC. albicans,
C. glabrata, and C. tropicalis that did not harbor fks mutations as
non-WT. The ECVs for anidulafungin and micafungin and the
CLSI broth microdilution method will help in monitoring the
emergence of echinocandin resistance among target species of
Candida.
ACKNOWLEDGMENTS
We thank all the hospital laboratories that contributedCandida isolates to
this study and Keile Wahle for excellent secretarial support.
J.F.M. received grants from Astellas, Basilea, andMerck not related to
this study. He has been a consultant to Basilea and Merck and received
speaker’s fees fromMerck andGilead. L.O.-Z. has received research grants
and speaking and consulting fees from Astellas, Merck, and Pfizer.
The findings and conclusions of this article are those of the authors
and do not necessarily represent the views of the Centers for Disease
Control and Prevention.
REFERENCES
1. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortho-
lary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S,
Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH,
Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Rich-
ardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID
Fungal Infection Study Group. 2012. ESCMID guideline for the diagno-
sis and management of Candida diseases 2012: non-neutropenic adult
patients. Clin. Microbiol. Infect. 18:19–37. http://dx.doi.org/10.1111
/1469-0691.12039.
2. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF,
Edwards JE, Filler SG, Fischer JF, Kullberg BJ, Ostrosky-Zeichner L,
Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guide-
lines for the management of candidiasis: 2009 update by the Infectious
Diseases Society of America. Clin. Infect. Dis. 48:503–535. http://dx.doi
.org/10.1086/596757.
3. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-
Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA,
Donnelly JP, Garbino J, Groll AH, Hope WW, Jensen HE, Kullberg BJ,
Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson
MD, Roilides E, Verweij PE, Cuenca-Estrella M, ESCMID Fungal In-
fection Study Group. 2012. ESCMID guideline for the diagnosis and
management of Candida diseases: adults with haematological malignan-
cies and after haematopoietic stem cell transplantation (HCT). Clin. Mi-
crobiol. Infect. 18:53–67. http://dx.doi.org/10.1111/1469-0691.12041.
TABLE 4 Application of ECVs to MIC distributions of anidulafungin
and micafungin for Candida strains tested for the presence of fks1 and
fks2 mutations using the CLSI broth microdilution methoda
Species (no. of
isolates tested)
Antifungal
agent
ECV
(g/ml)
No. of isolates by ECV
category (no. of isolates
showing mutations)
MIC ECV MIC ECV
C. albicans (52) Anidulafungin 0.12 42 (1) 10 (10)
Micafungin 0.03 31 (0) 21 (11)
C. glabrata (169) Anidulafungin 0.12 135 (2) 34 (28)
Micafungin 0.03 124 (0) 45 (30)
C. tropicalis (31) Anidulafungin 0.12 25 (1) 6 (5)
Micafungin 0.06 15 (0) 16 (6)
C. krusei (27) Anidulafungin 0.25 24 (0) 3 (3)
Micafungin 0.25 23 (0) 4 (3)
C. dubliniensis (2) Anidulafungin 0.12 1 (0) 1 (1)
Micafungin 0.12 1 (0) 1 (1)
a Data were compiled from references 6, 10, and 25 to 27.
ECVs for Candida and Echinocandins
February 2014 Volume 58 Number 2 aac.asm.org 921
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
4. Clinical and Laboratory Standards Institute. 2008. M27-A3. Reference
method for broth dilution antifungal susceptibility testing of yeasts, 3rd
ed. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2012. M27-S4. Reference
method for broth dilution antifungal susceptibility testing of yeasts, 4th
informational supplement. Clinical and Laboratory Standards Institute,
Wayne, PA.
6. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart
SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Testing.
2011. Clinical breakpoints for the echinocandins and Candida revisited:
integration of molecular, clinical, and microbiological data to arrive at
species-specific interpretive criteria. Drug Resist. Updat. 14:164–176.
http://dx.doi.org/10.1016/j.drup.2011.01.004.
7. Pfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility test-
ing of Candida spp. by use of Clinical and Laboratory Standards Institute
broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50:2846–
2856. http://dx.doi.org/10.1128/JCM.00937-12.
8. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S,
Jones RN, Turnidge J, Diekema DJ. 2010. Wild-type MIC distributions
and epidemiological cutoff values for the echinocandins andCandida spp.
J. Clin. Microbiol. 48:52–56. http://dx.doi.org/10.1128/JCM.01590-09.
9. Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Mouton JW,
Osterlund A, Rodloff A, Steinbakk M, Urbaskova P, Vatopoulos A.
2003. European harmonization ofMIC breakpoints for antimicrobial sus-
ceptibility testing of bacteria. J. Antimicrob. Chemother. 52:145–148.
http://dx.doi.org/10.1093/jac/dkg312.
10. Pfaller MA, Diekema DJ, Castanheira M, Jones RN. 2011. Definitions
and epidemiology of Candida species not susceptible to echinocandins.
Curr. Fungal Infect. Rep. 5:120–127. http://dx.doi.org/10.1007/s12281
-011-0053-y.
11. Simjee S, Silley P, Werling HO, Bywater R. 2008. Potential confusion
regarding the term ‘resistance’ in epidemiological surveys. J. Antimicrob.
Chemother. 61:228–229. http://dx.doi.org/10.1093/jac/dkm423.
12. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial suscep-
tibility breakpoints. Clin. Microbiol. Rev. 20:391–408. http://dx.doi.org
/10.1128/CMR.00047-06.
13. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. 2011.
Triazole and echinocandinMIC distributions with epidemiological cutoff
values for differentiation of wild-type strains from non-wild-type strains
of six uncommon species of Candida. J. Clin. Microbiol. 49:3800–3804.
http://dx.doi.org/10.1128/JCM.05047-11.
14. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B,
Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A,
Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SRG,
St-Germain G, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukin-
skas SRBS, Szeszs MW, Turnidge J. 2013. Interlaboratory variability of
caspofungin MICs for Candida spp. using CLSI and EUCAST methods:
should the clinical laboratory be testing this agent? Antimicrob. Agents
Chemother. 57:5836–5842. http://dx.doi.org/10.1128/AAC.01519-13.
15. Clinical and Laboratory Standards Institute. 2013. Minutes and agenda:
Annual Meeting of Subcommittee for Antifungal Susceptibility Testing,
Tampa, FL, 22 January 2013. Clinical and Laboratory Standards Institute,
Wayne, PA.
16. Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Lass-Flörl C, Martin-
Mazuelos E, Meis J, Pelaez T, Pfaller MA, Turnidge J. 2013. Multicenter
study of isavuconazole MIC distributions and epidemiological cutoff val-
ues forAspergillus spp. for the CLSIM38-A2 brothmicrodilutionmethod.
Antimicrob. Agents Chemother. 57:3823–3828. http://dx.doi.org/10.1128
/AAC.00636-13.
17. Canton E, Pemán J, Hervás D, Iñiguez C, Navarro D, Echeverría J,
Martínez-Alarcón J, Fontanals D, Gomila-Sard B, Buendía B, Torroba
L, Ayats J, Bratos A, Sánchez-Reus F, Fernández-Natal I, FUNGEMYCA
Study Group. 2012. Comparison of three statistical methods for estab-
lishing tentative wild-type population and epidemiological cutoff values
for echinocandins, amphotericin B, flucytosine, and sixCandida species as
determined by the colorimetric Sensititre YeastOne method. J. Clin. Mi-
crobiol. 50:3921–3926. http://dx.doi.org/10.1128/JCM.01730-12.
18. Turnidge J, Kahmeter G, Kronvall G. 2006. Statistical characterization of
bacterial wild-type MIC value distributions and determination of epide-
miological cutoff values. Clin. Microbiol. Infect. 12:418–425. http://dx
.doi.org/10.1111/j.1469-0691.2006.01377.x.
19. Turnidge J, Bordash G. 2007. Statistical methods for establishing quality
control limits in Clinical and Laboratory Standards Institute susceptibility
testing. Antimicrob. Agents Chemother. 51:2483–2488. http://dx.doi.org
/10.1128/AAC.01457-06.
20. Espinel-Ingroff A. 2003. In vitro antifungal activities of anidulafungin
andmicafungin, licensed agents and the investigational triazole posacona-
zole as determined by NCCLS methods for 12,052 fungal isolates: review
of literature. Rev. Iberoam. Micol. 20:121–136.
21. Messer SA, Jones RN, Fritsche TR. 2006. International surveillance of
Candida spp. andAspergillus spp.: report from the SENTRYAntimicrobial
Surveillance Program (2003). J. Clin. Microbiol. 44:1782–1787. http://dx
.doi.org/10.1128/JCM.44.5.1782-1787.2006.
22. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. 2013.
Echinocandin and triazole antifungal susceptibility profiles for clinical
opportunistic yeast and mold isolates collected from 2010 to 2011: appli-
cation of new CLSI clinical breakpoints and epidemiological cutoff values
for characterization of geographic and temporal trends of antifungal re-
sistance. J. Clin.Microbiol. 51:2571–2581. http://dx.doi.org/10.1128/JCM
.00308-13.
23. Canton E, Pemán J, Gobernado M, Alvarez E, Baquero F, Cisterna R,
Gil J, Martín-Mazuelos E, Rubio C, Sánchez-Sousa A, Serrano C. 2005.
Sensititre YeastOne caspofungin susceptibility testing of Candida clinical
isolates: correlation with results of NCCLS M27-A2 multicenter study.
Antimicrob. Agents Chemother. 49:1604–1607. http://dx.doi.org/10
.1128/AAC.49.4.1604-1607.2005.
24. Pfaller MA, Chaturvedi V, Diekema DJ, Ghannoum MA, Holliday NM,
Killian SB, Knapp CC, Messer SA, Miskov A, Ramani R. 2008. Clinical
evaluation of the Sensititre YeastOne colorimetric antifungal panel for
antifungal susceptibility testing of the echinocandins anidulafungin,
caspofungin, and micafungin. J. Clin. Microbiol. 46:2155–2159. http://dx
.doi.org/10.1128/JCM.00493-08.
25. Arendrup MC, Garcia-Effron G, Lass-Flörl C, Lopez AG, Rodriguez-
Tudela JL, Cuenca-Estrella M, Perlin DS. 2010. Echinocandin suscepti-
bility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI
M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and
Iso-Sensitest media. Antimicrob. Agents Chemother. 54:426–439. http:
//dx.doi.org/10.1128/AAC.01256-09.
26. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Moet GJ, Jones
RN. 2010. Comparison of EUCAST and Etest methods with the CLSI
broth microdilution method for echinocandin susceptibility testing of
Candida species. J. Clin. Microbiol. 48:1592–1599. http://dx.doi.org/10
.1128/JCM.02445-09.
27. Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller
T, Lockhart SR. 2010. FKS mutations and elevated echinocandin MIC
values among Candida glabrata isolates from US population-based sur-
veillance. Antimicrob. Agents Chemother. 54:5042–5047. http://dx.doi
.org/10.1128/AAC.00836-10.
Pfaller et al.
922 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
